Vergleich

PE-Labeled Human EGFRvIII Protein, His Tag (Site-specific conjugation) Europäischer Partner

ArtNr EGI-HP2E3-200tests
Hersteller ACROBiosystems
Menge 200 tests
Kategorie
Typ Proteins Recombinant
Format Powder
Specific against Human
Host HEK293
Konjugat/Tag HIS, PE
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Alias EGFRvIII
Lieferbar
Manufacturers Category
Protein / Fluorescent labeled protein
Description
PE-Labeled Human EGFRvIII, His Tag (EGI-HP2E3) is produced via site-specific conjugation of PE to Human EGFRvIII (25-378), His Tag under optimal conditions with a proprietary technology. Human EGFRvIII, His Tag (EGI-HP2E3) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Ser 378 (Accession # NP_001333870.1).
Molecule
EGFRvIII
Exp Region
Leu 25 - Ser 378
Storage
-20℃, aviod light
Shipping
RT
Stability
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Molecular Weight
42.2 kDa
Characteristics
This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 42.2 kDa.
Buffer
PBS, 0.5% BSA, pH7.4
Background
The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer.
The type III EGF deletion mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors. This tumor-specific antigen is ligand-independent, contains a constitutively active tyrosine kinase domain, and has been shown to be present in a number of human malignancies. EGFRvIII has been selected as a target for CAR-modified T-cell studies in recent years.

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 200 tests
Lieferbar: In stock
lieferbar

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?
 
Schließen